

## S 3116

### Ending the Diagnostic Odyssey Act of 2019

**Congress:** 116 (2019–2021, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Dec 19, 2019

**Current Status:** Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S7

**Latest Action:** Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S7211) (Dec 19, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/senate-bill/3116>

### Sponsor

**Name:** Sen. Collins, Susan M. [R-ME]

**Party:** Republican • **State:** ME • **Chamber:** Senate

### Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Jones, Doug [D-AL]	D · AL		Dec 19, 2019
Sen. McSally, Martha [R-AZ]	R · AZ		Dec 19, 2019
Sen. Menendez, Robert [D-NJ]	D · NJ		Dec 19, 2019
Sen. Smith, Tina [D-MN]	D · MN		Mar 5, 2020

### Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Dec 19, 2019

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
116 HR 4393	Related bill	Sep 19, 2019: Referred to the Subcommittee on Health.
116 HR 4144	Related bill	Aug 5, 2019: Referred to the Subcommittee on Health.

## **Ending the Diagnostic Odyssey Act of 2019**

This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals.

Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease.

The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.

### **Actions Timeline**

---

- **Dec 19, 2019:** Introduced in Senate
- **Dec 19, 2019:** Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S7211)